Literature DB >> 23707559

Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.

Shuwei Qiu1, Daquan Huang, Deling Yin, Fangcheng Li, Xiangping Li, Hsiang-Fu Kung, Ying Peng.   

Abstract

Deregulation of microRNAs (miRNAs) is implicated in tumor progression. We attempt to identify the tumor suppressive miRNA not only down-regulated in glioblastoma multiforme (GBM) but also potent to inhibit the oncogene EZH2, and then investigate the biological function and pathophysiologic role of the candidate miRNA in GBM. In this study, we show that miRNA-138 is reduced in both GBM clinical specimens and cell lines, and is effective to inhibit EZH2 expression. Moreover, high levels of miR-138 are associated with long overall and progression-free survival of GBM patients from The Cancer Genome Atlas dataset (TCGA) data portal. Ectopic expression of miRNA-138 effectively inhibits GBM cell proliferation in vitro and tumorigenicity in vivo through inducing cell cycles G1/S arrest. Mechanism investigation reveals that miRNA-138 acquires tumor inhibition through directly targeting EZH2, CDK6, E2F2 and E2F3. Moreover, an EZH2-mediated signal loop, EZH2-CDK4/6-pRb-E2F1, is probably involved in GBM tumorigenicity, and this loop can be blocked by miRNA-138. Additionally, miRNA-138 negatively correlates to mRNA levels of EZH2 and CDK6 among GBM clinical samples from both TCGA and our small amount datasets. In conclusion, our data demonstrate a tumor suppressive role of miRNA-138 in GBM tumorigenicity, suggesting a potential application in GBM therapy.
Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma multiforme/microRNA-138/EZH2/CDK6/tumorigenicity/TCGA

Mesh:

Substances:

Year:  2013        PMID: 23707559     DOI: 10.1016/j.bbadis.2013.05.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  50 in total

1.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  Identification of conserved and novel microRNAs in cerebral ischemia-reperfusion injury of rat using deep sequencing.

Authors:  Chunmei Wang; Yanyou Pan; Baohua Cheng; Jing Chen; Bo Bai
Journal:  J Mol Neurosci       Date:  2014-07-26       Impact factor: 3.444

Review 3.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

4.  Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells.

Authors:  Hui Yang; Yue Tang; Wei Guo; Yuwen Du; Yuanyuan Wang; Ping Li; Wenqiao Zang; Xiaojun Yin; Huaqi Wang; Heying Chu; Guojun Zhang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-04-02

5.  Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.

Authors:  Jharna Datta; Mozaffarul Islam; Samidha Dutta; Sounak Roy; Quintin Pan; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2016-03-19       Impact factor: 5.337

6.  miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export.

Authors:  Matthew B Hudson; Myra E Woodworth-Hobbs; Bin Zheng; Jill A Rahnert; Mitsi A Blount; Jennifer L Gooch; Charles D Searles; S Russ Price
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-11       Impact factor: 4.249

7.  MicroRNA-138 targets SP1 to inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells.

Authors:  Chongzhong Liu; Jiankang Zhu; Fengyue Liu; Yadong Wang; Min Zhu
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 8.  Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.

Authors:  Agnieszka Bronisz; Jakub Godlewski; E Antonio Chiocca
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

9.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

10.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.